## Protocol Section
### Identification Module
**NCT ID:** NCT06416462

**Brief Title:** Action of Photodynamic Therapy on Wound Quality and Tissue Repair in the Diabetic Foot

**Official Title:** Action of Photodynamic Therapy on Wound Quality and Tissue Repair in the Diabetic Foot: Double Blind Randomized Controlled Clinical Study

#### Organization Study ID Info
**ID:** 6.296.354
#### Organization
**Class:** OTHER
**Full Name:** University of Nove de Julho
### Status Module
#### Completion Date
**Date:** 2024-12-30

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-16

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-14

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2024-11-30

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-07-30

**Type:** ESTIMATED

**Status Verified Date:** 2023-10

#### Study First Post Date
**Date:** 2024-05-16
**Type:** ACTUAL
**Study First Submit Date:** 2023-10-02
**Study First Submit QC Date:** 2024-05-14
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** OTHER

**Name:** University of Nove de Julho

#### Responsible Party

**Investigator Affiliation:** University of Nove de Julho

**Investigator Full Name:** Kristianne Porta Santos Fernandes

**Investigator Title:** Clinical colaborator

**Type:** PRINCIPAL_INVESTIGATOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

### Description Module

**Brief Summary:** Diabetic foot ulcer affects 10.5% of the Brazilian/world population, compromising the quality of life of these patients and burdening the public health system. Studies show that antimicrobial photodynamic therapy (aPDT) accelerates its repair, however, there is not enough evidence for decision-making in clinical practice, which prevents this treatment from being used on a large scale. Controlled and randomized clinical studies are needed to increase the level of evidence on this subject, promoting the improvement of the quality of life of people affected by diabetic foot ulcers. The aim of this study is to analyze the action of antimicrobial photodynamic therapy on the quality of the wound and tissue repair process using the Bates-Jensen scale in people affected by diabetic foot wounds.

**Detailed Description:** Diabetic foot ulcer affects 10.5% of the Brazilian/world population, compromising the quality of life of these patients and burdening the public health system. Studies show that antimicrobial photodynamic therapy (aPDT) accelerates its repair, however, there is not enough evidence for decision-making in clinical practice, which prevents this treatment from being used on a large scale. Controlled and randomized clinical studies are needed to increase the level of evidence on this subject, promoting the improvement of the quality of life of people affected by diabetic foot ulcers. The aim of this study is to analyze the action of antimicrobial photodynamic therapy on the quality of the wound and tissue repair process using the Bates-Jensen scale in people affected by diabetic foot wounds. A clinical, controlled, randomized and double-blind study will be carried out. Patients will be randomized (1:1) into 2 groups: (1) experimental (n= 45) - standard care from the Polyclinic wound sector + aPDT and (2) control (n= 45) - standard care + simulation of use aPDT with equipment off). All patients will be seen three times a week, with 10 sessions of aPDT or simulation performed by the same operator. A cluster with an average radiant power of 100 mW, radiant energy per emitter of 6 J/cm² of red light (wavelength 660 nm) will be used. The research will be carried out in a Municipal Health Center in the city of Rio de Janeiro. Patients affected by neuropathic wounds of the diabetic foot, assisted by the Programmatic Care Health Coordination will be included 5.1. The initial assessment will consist of collecting data from medical records to establish the sociodemographic and clinical profile of patients affected by diabetic foot injuries.) by a researcher blinded to the interventions. This scale assesses the size of the lesion, depth, borders, detachment, type of necrotic tissue, amount of necrotic tissue, type of exudate, amount of exudate, skin color around the wound, perilesional tissue edema, perilesional tissue hardening, granulation tissue, epithelialization. As secondary outcomes: the sensitivity of the foot will be evaluated, through neurological evaluation with tuning fork and monofilament, the instrument for assessing quality of life - Diabetes-21, the Wagner Scale, the evaluation of the degree of ischemia by the Fontaine scale and Runtherford, the WiFi and Taxonomy Nursing Outcomes Classification scale that assesses skin integrity. Data from this research will be collected after approval by the ethics committee of Universidade Nove de Julho and the City Hall of Rio de Janeiro.

### Conditions Module

**Conditions:**

- Diabetic Foot Ulcer

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** DOUBLE

**Who Masked:**

- PARTICIPANT

- CARE_PROVIDER

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 90

**Type:** ESTIMATED

**Phases:**

- NA

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Participants in the control group will be treated in exactly the same way as the aPDT group, however the light treatment will be simulated. The device will be placed in position, however it will be switched off. After three weeks of monitoring in the control group, the patient will be informed that they were in the placebo group and will be offered treatment with aPDT and irradiation, for ethical reasons.

**Intervention Names:**

- Procedure: antimicrobial photodynamic therapy

**Label:** group control

**Type:** PLACEBO_COMPARATOR

#### Arm Group 2

**Description:** In the experimental group (aPDT), 1% methylene blue applied with the aid of a syringe will be used as a photosensitizer (with a pre-irradiation time of 5 minutes, 6 J of red laser will be applied.

**Intervention Names:**

- Procedure: antimicrobial photodynamic therapy

**Label:** experiment group

**Type:** ACTIVE_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- experiment group

- group control

**Description:** When starting the research, all wounds, regardless of the study group, will be cleaned with 0.9% saline solution (SF0.9%), using a 40x12 needle and a 500ml bottle of SF0.9%, in order to maintain pressure. for equal cleaning of all wounds and a hydrofiber plate with silver was used as standard coverage. Experimental group (n=45): When starting the intervention, all services in both groups will follow the cleaning standard described previously. In the aPDT group, 1% methylene blue will be used as a photosensitizer applied with the aid of a syringe (with a pre-irradiation time of 5 minutes), 6 J of laser will be applied.

**Name:** antimicrobial photodynamic therapy

**Type:** PROCEDURE

### Outcomes Module

#### Primary Outcomes

**Description:** The Bates-Jensen Scale is an effective tool for wound assessment. In its current version, it includes 13 characteristics to be evaluated: size, depth, edges, undermining, type of necrotic tissue, amount of necrotic tissue, exudate type, exudate amount, skin color around the wound, perilesional tissue edema, perilesional tissue induration, granulation tissue, and epithelialization.

Each item on the scale is scored from 1 to 5:

minimum values indicate the best wound condition,

maximum values represent the worst condition.

The total score is obtained by summing all the items and can range from 13 to 65 points, with HIGHER scores indicating WORSE wound conditions.

**Measure:** Bates-Jensen Wound Assesment Tool

**Time Frame:** Before the intervention

**Description:** The Bates-Jensen Scale is an effective tool for wound assessment. In its current version, it includes 13 characteristics to be evaluated: size, depth, edges, undermining, type of necrotic tissue, amount of necrotic tissue, exudate type, exudate amount, skin color around the wound, perilesional tissue edema, perilesional tissue induration, granulation tissue, and epithelialization.

Each item on the scale is scored from 1 to 5:

minimum values indicate the best wound condition,

maximum values represent the worst condition.

The total score is obtained by summing all the items and can range from 13 to 65 points, with HIGHER scores indicating WORSE wound conditions.

**Measure:** Bates-Jensen Wound Assesment Tool

**Time Frame:** First day after intervention

**Description:** The Bates-Jensen Scale is an effective tool for wound assessment. In its current version, it includes 13 characteristics to be evaluated: size, depth, edges, undermining, type of necrotic tissue, amount of necrotic tissue, exudate type, exudate amount, skin color around the wound, perilesional tissue edema, perilesional tissue induration, granulation tissue, and epithelialization.

Each item on the scale is scored from 1 to 5:

minimum values indicate the best wound condition,

maximum values represent the worst condition.

The total score is obtained by summing all the items and can range from 13 to 65 points, with HIGHER scores indicating WORSE wound conditions.

**Measure:** Bates-Jensen scale

**Time Frame:** Third day after intervention

**Description:** The Bates-Jensen Scale is an effective tool for wound assessment. In its current version, it includes 13 characteristics to be evaluated: size, depth, edges, undermining, type of necrotic tissue, amount of necrotic tissue, exudate type, exudate amount, skin color around the wound, perilesional tissue edema, perilesional tissue induration, granulation tissue, and epithelialization.

Each item on the scale is scored from 1 to 5:

minimum values indicate the best wound condition,

maximum values represent the worst condition.

The total score is obtained by summing all the items and can range from 13 to 65 points, with HIGHER scores indicating WORSE wound conditions.

**Measure:** Bates-Jensen scale

**Time Frame:** Fifth day after intervention

**Description:** The Bates-Jensen Scale is an effective tool for wound assessment. In its current version, it includes 13 characteristics to be evaluated: size, depth, edges, undermining, type of necrotic tissue, amount of necrotic tissue, exudate type, exudate amount, skin color around the wound, perilesional tissue edema, perilesional tissue induration, granulation tissue, and epithelialization. Each item on the scale is scored from 1 to 5, where 1 indicates the best wound condition, and 5 represents the worst condition. The total score is obtained by summing all the items and can range from 13 to 65 points, with higher scores indicating worse wound conditions.

**Measure:** Bates-Jensen scale

**Time Frame:** Tenth day after intervention

#### Secondary Outcomes

**Description:** Evaluate the effect of aPDT on quality of life using the Diabetes-21 instrument

**Measure:** Diabetes-21 instrument

**Time Frame:** Before the intervention

**Description:** Evaluate the effect of aPDT on quality of life using the Diabetes-21 instrument

**Measure:** Diabetes-21 instrument

**Time Frame:** First day after intervention

**Description:** Evaluate the effect of aPDT on quality of life using the Diabetes-21 instrument

**Measure:** Diabetes-21 instrument

**Time Frame:** Third day after intervention

**Description:** Evaluate the effect of aPDT on quality of life using the Diabetes-21 instrument

**Measure:** Diabetes-21 instrument

**Time Frame:** The fifth day after intervention

**Description:** Evaluate the effect of aPDT on quality of life using the Diabetes-21 instrument

**Measure:** Diabetes-21 instrument

**Time Frame:** Tenth day after intervention

**Description:** Classify the diabetic foot wound with the Wagner Scale

**Measure:** Wagner Scale

**Time Frame:** Before the intervention

**Description:** Classify the diabetic foot wound with the Wagner Scale

**Measure:** Wagner Scale

**Time Frame:** First day after intervention

**Description:** Classify the diabetic foot wound with the Wagner Scale

**Measure:** Wagner Scale

**Time Frame:** Third day after intervention

**Description:** Classify the diabetic foot wound with the Wagner Scale

**Measure:** Wagner Scale

**Time Frame:** Fifth day after intervention

**Description:** Classify the diabetic foot wound with the Wagner Scale

**Measure:** Wagner Scale

**Time Frame:** Tenth day after intervention

**Description:** Assess the risk of amputation using the WiFi scale

**Measure:** WiFi scale

**Time Frame:** Before the intervention

**Description:** Assess the risk of amputation using the WiFi scale

**Measure:** WiFi scale

**Time Frame:** First day after intervention

**Description:** Assess the risk of amputation using the WiFi scale

**Measure:** WiFi scale

**Time Frame:** Third day after intervention

**Description:** Assess the risk of amputation using the WiFi scale

**Measure:** WiFi scale

**Time Frame:** Fifth day after intervention

**Description:** Assess the risk of amputation using the WiFi scale

**Measure:** WiFi scale

**Time Frame:** Tenth day after intervention

**Description:** Assess skin integrity using the Nursing Outcomes Classification Taxonomy

**Measure:** Nursing Outcomes Classification Taxonomy

**Time Frame:** Before the intervention

**Description:** Assess skin integrity using the Nursing Outcomes Classification Taxonomy

**Measure:** Nursing Outcomes Classification Taxonomy

**Time Frame:** First day after intervention

**Description:** Assess skin integrity using the Nursing Outcomes Classification Taxonomy

**Measure:** Nursing Outcomes Classification Taxonomy

**Time Frame:** Third day after intervention

**Description:** Assess skin integrity using the Nursing Outcomes Classification Taxonomy

**Measure:** Nursing Outcomes Classification Taxonomy

**Time Frame:** Fifth day after intervention

**Description:** Assess skin integrity using the Nursing Outcomes Classification Taxonomy

**Measure:** Nursing Outcomes Classification Taxonomy

**Time Frame:** Tenth day after intervention

**Description:** Rutherford et al. (1997) also base their classification on the degree of ischemia, with some differences in the parameters assessed: asymptomatic (0); mild claudication (1); moderate claudication (2); severe claudication (3); ischemic pain at rest (4); minor tissue loss (5); major tissue loss (6). The higher value corresponds to the worst result.

**Measure:** Runtherford Scale for ischemia evaluation

**Time Frame:** Before the intervention

**Description:** Rutherford et al. (1997) also base their classification on the degree of ischemia, with some differences in the parameters assessed: asymptomatic (0); mild claudication (1); moderate claudication (2); severe claudication (3); ischemic pain at rest (4); minor tissue loss (5); major tissue loss (6). The higher value corresponds to the worst result.

**Measure:** Runtherford Scale for ischemia evaluation

**Time Frame:** First day after intervention

**Description:** Rutherford et al. (1997) also base their classification on the degree of ischemia, with some differences in the parameters assessed: asymptomatic (0); mild claudication (1); moderate claudication (2); severe claudication (3); ischemic pain at rest (4); minor tissue loss (5); major tissue loss (6). The higher value corresponds to the worst result.

**Measure:** Runtherford Scale for ischemia evaluation

**Time Frame:** Third day after intervention

**Description:** Rutherford et al. (1997) also base their classification on the degree of ischemia, with some differences in the parameters assessed: asymptomatic (0); mild claudication (1); moderate claudication (2); severe claudication (3); ischemic pain at rest (4); minor tissue loss (5); major tissue loss (6). The higher value corresponds to the worst result.

**Measure:** Runtherford Scale for ischemia evaluation

**Time Frame:** Fifth day after intervention

**Description:** Rutherford et al. (1997) also base their classification on the degree of ischemia, with some differences in the parameters assessed: asymptomatic (0); mild claudication (1); moderate claudication (2); severe claudication (3); ischemic pain at rest (4); minor tissue loss (5); major tissue loss (6). The higher value corresponds to the worst result.

**Measure:** Runtherford Scale for ischemia evaluation

**Time Frame:** Tenth day after intervention

**Description:** Assess the protective sensitivity of the feet through the monofilament and tuning fork test

**Measure:** protective sensitivity of the feet

**Time Frame:** Before the intervention

**Description:** Assess the protective sensitivity of the feet through the monofilament and tuning fork test

**Measure:** protective sensitivity of the feet

**Time Frame:** First day after intervention

**Description:** Assess the protective sensitivity of the feet through the monofilament and tuning fork test

**Measure:** protective sensitivity of the feet

**Time Frame:** Third day after intervention

**Description:** Assess the protective sensitivity of the feet through the monofilament and tuning fork test

**Measure:** protective sensitivity of the feet

**Time Frame:** Fifth day after intervention

**Description:** Assess the protective sensitivity of the feet through the monofilament and tuning fork test

**Measure:** protective sensitivity of the feet

**Time Frame:** Tenth day after intervention

**Description:** Fontaine et al. (1957) primarily rely on the degree of limb ischemia, evaluating the following parameters: asymptomatic (I); mild claudication (IIa); moderate to severe claudication (IIb); rest pain (III); gangrene or ulceration (IV).

**Measure:** Fontaine Classification

**Time Frame:** Before the intervention

**Description:** Fontaine et al. (1957) primarily rely on the degree of limb ischemia, evaluating the following parameters: asymptomatic (I); mild claudication (IIa); moderate to severe claudication (IIb); rest pain (III); gangrene or ulceration (IV).

**Measure:** Fontaine Classification

**Time Frame:** First day after intervention

**Description:** Fontaine et al. (1957) primarily rely on the degree of limb ischemia, evaluating the following parameters: asymptomatic (I); mild claudication (IIa); moderate to severe claudication (IIb); rest pain (III); gangrene or ulceration (IV).

**Measure:** Fontaine Classification

**Time Frame:** Third day after intervention

**Description:** Fontaine et al. (1957) primarily rely on the degree of limb ischemia, evaluating the following parameters: asymptomatic (I); mild claudication (IIa); moderate to severe claudication (IIb); rest pain (III); gangrene or ulceration (IV).

**Measure:** Fontaine Classification

**Time Frame:** Fifth day after intervention

**Description:** Fontaine et al. (1957) primarily rely on the degree of limb ischemia, evaluating the following parameters: asymptomatic (I); mild claudication (IIa); moderate to severe claudication (IIb); rest pain (III); gangrene or ulceration (IV).

**Measure:** Fontaine Classification

**Time Frame:** Tenth day after intervention

**Description:** To assess vibratory sensitivity, a 128Hz tuning fork is applied to a bony area (e.g., elbow, clavicle, sternum, chin) to demonstrate the expected sensation. The participant then closes their eyes, and the tuning fork is applied with constant pressure to the dorsal side of the hallux's distal phalanx or another toe if the hallux is missing. If all phalanges are amputated, it's applied to the nearby area. The tuning fork is held in place until the participant reports the vibration has ceased. The test is repeated twice, with at least one "simulated" application where the tuning fork doesn't vibrate. A positive test result is when the participant correctly identifies vibration in at least two out of three applications, while a negative result is when they inaccurately identify vibration in two out of three applications, indicating a lack of vibratory sensitivity (IWGDF, 2019).

**Measure:** Vibration Sensation

**Time Frame:** Before the intervention

**Description:** To assess vibratory sensitivity, a 128Hz tuning fork is applied to a bony area (e.g., elbow, clavicle, sternum, chin) to demonstrate the expected sensation. The participant then closes their eyes, and the tuning fork is applied with constant pressure to the dorsal side of the hallux's distal phalanx or another toe if the hallux is missing. If all phalanges are amputated, it's applied to the nearby area. The tuning fork is held in place until the participant reports the vibration has ceased. The test is repeated twice, with at least one "simulated" application where the tuning fork doesn't vibrate. A positive test result is when the participant correctly identifies vibration in at least two out of three applications, while a negative result is when they inaccurately identify vibration in two out of three applications, indicating a lack of vibratory sensitivity (IWGDF, 2019).

**Measure:** Vibration Sensation

**Time Frame:** First day after intervention

**Description:** To assess vibratory sensitivity, a 128Hz tuning fork is applied to a bony area (e.g., elbow, clavicle, sternum, chin) to demonstrate the expected sensation. The participant then closes their eyes, and the tuning fork is applied with constant pressure to the dorsal side of the hallux's distal phalanx or another toe if the hallux is missing. If all phalanges are amputated, it's applied to the nearby area. The tuning fork is held in place until the participant reports the vibration has ceased. The test is repeated twice, with at least one "simulated" application where the tuning fork doesn't vibrate. A positive test result is when the participant correctly identifies vibration in at least two out of three applications, while a negative result is when they inaccurately identify vibration in two out of three applications, indicating a lack of vibratory sensitivity (IWGDF, 2019).

**Measure:** Vibration Sensation

**Time Frame:** Third day after intervention

**Description:** To assess vibratory sensitivity, a 128Hz tuning fork is applied to a bony area (e.g., elbow, clavicle, sternum, chin) to demonstrate the expected sensation. The participant then closes their eyes, and the tuning fork is applied with constant pressure to the dorsal side of the hallux's distal phalanx or another toe if the hallux is missing. If all phalanges are amputated, it's applied to the nearby area. The tuning fork is held in place until the participant reports the vibration has ceased. The test is repeated twice, with at least one "simulated" application where the tuning fork doesn't vibrate. A positive test result is when the participant correctly identifies vibration in at least two out of three applications, while a negative result is when they inaccurately identify vibration in two out of three applications, indicating a lack of vibratory sensitivity (IWGDF, 2019).

**Measure:** Vibration Sensation

**Time Frame:** Fifth day after intervention

**Description:** To assess vibratory sensitivity, a 128Hz tuning fork is applied to a bony area (e.g., elbow, clavicle, sternum, chin) to demonstrate the expected sensation. The participant then closes their eyes, and the tuning fork is applied with constant pressure to the dorsal side of the hallux's distal phalanx or another toe if the hallux is missing. If all phalanges are amputated, it's applied to the nearby area. The tuning fork is held in place until the participant reports the vibration has ceased. The test is repeated twice, with at least one "simulated" application where the tuning fork doesn't vibrate. A positive test result is when the participant correctly identifies vibration in at least two out of three applications, while a negative result is when they inaccurately identify vibration in two out of three applications, indicating a lack of vibratory sensitivity (IWGDF, 2019).

**Measure:** Vibration Sensation

**Time Frame:** Tenth day after intervention

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* both sexes
* chronic wounds originating from the neuropathic diabetic foot
* contaminated lesions
* total score obtained on the Bates-Jensen scale between 13 and 60
* who submits all requested exams

Exclusion Criteria:

* wounds with etiologies that are not related to the diabetic foot
* ischemic diabetic foot who has an ankle-brachial index with a value between 0.7 and 1.3.
* glycated hemoglobin greater than 8%.

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** raquel.mesquita@gmail.com

**Name:** Raquel Agnelli Mesquita-Ferrari, PhD

**Phone:** +55 (11) 2633-9000

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** São Paulo

**Contacts:**

***Contact 1:***

- **Email:** annacrth@gmail.com

- **Name:** Raquel R Agnelli Mesquita-Ferrari

- **Role:** CONTACT

**Country:** Brazil

**Facility:** Raquel Agnelli Mesquita-Ferrari

**State:** SP

**Zip:** 11030-480

#### Overall Officials

**Official 1:**

**Affiliation:** University of Nove de Julho

**Name:** Raquel Agnelli Mesquita-Ferrari, PhD

**Role:** STUDY_DIRECTOR

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000003925

- Term: Diabetic Angiopathies

- ID: D000014652

- Term: Vascular Diseases

- ID: D000002318

- Term: Cardiovascular Diseases

- ID: D000007871

- Term: Leg Ulcer

- ID: D000012883

- Term: Skin Ulcer

- ID: D000012871

- Term: Skin Diseases

- ID: D000048909

- Term: Diabetes Complications

- ID: D000003920

- Term: Diabetes Mellitus

- ID: D000004700

- Term: Endocrine System Diseases

- ID: D000003929

- Term: Diabetic Neuropathies

- ID: D000005534

- Term: Foot Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC26

- Name: Wounds and Injuries

- Abbrev: All

- Name: All Conditions

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: BC14

- Name: Heart and Blood Diseases

- Abbrev: BC17

- Name: Skin and Connective Tissue Diseases

- Abbrev: BC19

- Name: Gland and Hormone Related Diseases

- Abbrev: BC18

- Name: Nutritional and Metabolic Diseases

- Abbrev: BC10

- Name: Nervous System Diseases

- Abbrev: BC05

- Name: Musculoskeletal Diseases

### Condition Browse Module - Browse Leaves

- ID: M17685

- Name: Wounds and Injuries

- Relevance: LOW

- As Found: Unknown

- ID: M17206

- Name: Ulcer

- Relevance: LOW

- As Found: Unknown

- ID: M19933

- Name: Diabetic Foot

- Relevance: HIGH

- As Found: Diabetic Foot

- ID: M18919

- Name: Foot Ulcer

- Relevance: HIGH

- As Found: Foot Ulcer

- ID: M7120

- Name: Diabetic Angiopathies

- Relevance: LOW

- As Found: Unknown

- ID: M17400

- Name: Vascular Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M10883

- Name: Leg Ulcer

- Relevance: LOW

- As Found: Unknown

- ID: M15686

- Name: Skin Ulcer

- Relevance: LOW

- As Found: Unknown

- ID: M15674

- Name: Skin Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M7115

- Name: Diabetes Mellitus

- Relevance: LOW

- As Found: Unknown

- ID: M26004

- Name: Diabetes Complications

- Relevance: LOW

- As Found: Unknown

- ID: M7862

- Name: Endocrine System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M7124

- Name: Diabetic Neuropathies

- Relevance: LOW

- As Found: Unknown

- ID: M8658

- Name: Foot Diseases

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000017719

- Term: Diabetic Foot

- ID: D000016523

- Term: Foot Ulcer

### Intervention Browse Module - Browse Branches

- Abbrev: Infe

- Name: Anti-Infective Agents

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: PhSol

- Name: Pharmaceutical Solutions

- Abbrev: CNSDep

- Name: Central Nervous System Depressants

- Abbrev: Derm

- Name: Dermatologic Agents

- Abbrev: Ot

- Name: Other Dietary Supplements

### Intervention Browse Module - Browse Leaves

- ID: M4222

- Name: Anti-Bacterial Agents

- Relevance: HIGH

- As Found: Residents

- ID: M21860

- Name: Pharmaceutical Solutions

- Relevance: LOW

- As Found: Unknown

- ID: M4214

- Name: Anti-Infective Agents

- Relevance: HIGH

- As Found: Residents

- ID: M11726

- Name: Methylene Blue

- Relevance: LOW

- As Found: Unknown

- ID: M4854

- Name: Benzocaine

- Relevance: LOW

- As Found: Unknown

- ID: M19608

- Name: Photosensitizing Agents

- Relevance: LOW

- As Found: Unknown

- ID: T433

- Name: Tannic Acid

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: D000000890

- Term: Anti-Infective Agents

- ID: D000000900

- Term: Anti-Bacterial Agents

### Misc Info Module

- Version Holder: 2024-05-31
